Research News
The latest news and featured articles about blood cancer research supported by 青云体育
Research News
The latest news and featured articles about blood cancer research supported by 青云体育
Please visit the main for all blood cancer updates including patient care, advocacy and fundraising.
For the latest from 青云体育 Research please follow us on Twitter:
Some of our latest news:
FDA Approves New Formulation of Important Childhood Leukemia Drug
The U.S. Food and Drug Administration yesterday approved nelarabine injection, a critical treatment for T-cell acute lymphoblastic leukemia (T-ALL), an aggressive blood cancer that is most common in children.
Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-mutant AML
SAN DIEGO, Feb. 09, 2023 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company鈥檚 novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Exciting new publications supported by 青云体育: March 2022
Editor's Choice: three peer reviewed and 青云体育 supported publications from Spring 2022